354 related articles for article (PubMed ID: 28176813)
1. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape.
Lebbink RJ; de Jong DC; Wolters F; Kruse EM; van Ham PM; Wiertz EJ; Nijhuis M
Sci Rep; 2017 Feb; 7():41968. PubMed ID: 28176813
[TBL] [Abstract][Full Text] [Related]
2. The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape.
Darcis G; Binda CS; Klaver B; Herrera-Carrillo E; Berkhout B; Das AT
Viruses; 2019 Mar; 11(3):. PubMed ID: 30871200
[TBL] [Abstract][Full Text] [Related]
3. Multiplexed
Ophinni Y; Miki S; Hayashi Y; Kameoka M
Viruses; 2020 Oct; 12(11):. PubMed ID: 33126728
[TBL] [Abstract][Full Text] [Related]
4. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
5. Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection.
Wang Q; Liu S; Liu Z; Ke Z; Li C; Yu X; Chen S; Guo D
Virus Res; 2018 May; 250():21-30. PubMed ID: 29625148
[TBL] [Abstract][Full Text] [Related]
6. Elimination of infectious HIV DNA by CRISPR-Cas9.
Das AT; Binda CS; Berkhout B
Curr Opin Virol; 2019 Oct; 38():81-88. PubMed ID: 31450074
[TBL] [Abstract][Full Text] [Related]
7. Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9.
Yoder KE; Bundschuh R
Sci Rep; 2016 Jul; 6():29530. PubMed ID: 27404981
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-CAS Replacing Antiviral Drugs against HIV: An Update.
Hashmat R; Yousaf MZ; Rahman Z; Anjum KM; Yaqoob A; Imran M
Crit Rev Eukaryot Gene Expr; 2020; 30(1):77-83. PubMed ID: 32421986
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
[TBL] [Abstract][Full Text] [Related]
10. A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures.
Wang G; Zhao N; Berkhout B; Das AT
Cell Rep; 2016 Dec; 17(11):2819-2826. PubMed ID: 27974196
[TBL] [Abstract][Full Text] [Related]
11. RNA-guided gene editing of the murine gammaherpesvirus 68 genome reduces infectious virus production.
Foreman HC; Kirillov V; Paniccia G; Catalano D; Andrunik T; Gupta S; Krug LT; Zhang Y
PLoS One; 2021; 16(6):e0252313. PubMed ID: 34086743
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Cas9 by viral proteins Tat and Rev for HIV-1 inactivation.
Vergara-Mendoza M; Gomez-Quiroz LE; Miranda-Labra RU; Fuentes-Romero LL; Romero-Rodríguez DP; González-Ruiz J; Hernández-Rizo S; Viveros-Rogel M
Antiviral Res; 2020 Aug; 180():104856. PubMed ID: 32579898
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 Inhibits Multiple Steps of HIV-1 Infection.
Yin L; Hu S; Mei S; Sun H; Xu F; Li J; Zhu W; Liu X; Zhao F; Zhang D; Cen S; Liang C; Guo F
Hum Gene Ther; 2018 Nov; 29(11):1264-1276. PubMed ID: 29644868
[TBL] [Abstract][Full Text] [Related]
14. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.
Roychoudhury P; De Silva Feelixge H; Reeves D; Mayer BT; Stone D; Schiffer JT; Jerome KR
BMC Biol; 2018 Jul; 16(1):75. PubMed ID: 29996827
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats.
Lai M; Maori E; Quaranta P; Matteoli G; Maggi F; Sgarbanti M; Crucitta S; Pacini S; Turriziani O; Antonelli G; Heeney JL; Freer G; Pistello M
J Virol; 2021 Nov; 95(23):e0135821. PubMed ID: 34549986
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
[TBL] [Abstract][Full Text] [Related]
17. Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication.
Khanal S; Cao D; Zhang J; Zhang Y; Schank M; Dang X; Nguyen LNT; Wu XY; Jiang Y; Ning S; Zhao J; Wang L; Gazzar ME; Moorman JP; Yao ZQ
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146709
[TBL] [Abstract][Full Text] [Related]
18. A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes.
Huang Z; Nair M
Sci Rep; 2017 Jul; 7(1):5955. PubMed ID: 28729655
[TBL] [Abstract][Full Text] [Related]
19. Anti-HIV-1 potency of the CRISPR/Cas9 system insufficient to fully inhibit viral replication.
Ueda S; Ebina H; Kanemura Y; Misawa N; Koyanagi Y
Microbiol Immunol; 2016 Jul; 60(7):483-96. PubMed ID: 27278725
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape.
Wang G; Zhao N; Berkhout B; Das AT
Mol Ther; 2016 Mar; 24(3):522-6. PubMed ID: 26796669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
